Provided by Tiger Trade Technology Pte. Ltd.

Rigel Pharmaceuticals

47.15
+0.18000.38%
Post-market: 47.150.00000.00%19:30 EDT
Volume:185.67K
Turnover:8.75M
Market Cap:880.76M
PE:2.87
High:48.00
Open:47.66
Low:46.45
Close:46.97
52wk High:52.24
52wk Low:24.95
Shares:18.68M
Float Shares:14.85M
Volume Ratio:0.88
T/O Rate:1.25%
Dividend:- -
Dividend Rate:- -
EPS(TTM):16.45
EPS(LYR):19.48
ROE:126.90%
ROA:14.95%
PB:2.07
PE(LYR):2.42

Loading ...

Rigel Pharmaceuticals - Appoints Alison L. Hannah as Executive Vice President and Chief Medical Officer Effective July 1, 2026 - SEC Filing

THOMSON REUTERS
·
Jul 02

Rigel Names Board Member Alison Hannah Chief Medical Officer, Replacing Lisa Rojkjaer

Reuters
·
Jul 01

Rigel Appoints Board Member Alison L. Hannah, M.d. as Chief Medical Officer

THOMSON REUTERS
·
Jul 01

Rigel Pharmaceuticals pays $70 million upfront for global rights to Arvinas-Pfizer breast cancer drug VEPPANU

Reuters
·
Jun 18

Rigel Deal for VEPPANU Cleared, Arvinas Receives Payment

TIPRANKS
·
Jun 17

Rigel Pharmaceuticals Closes Licensing Deal for Breast Cancer Drug Veppanu

MT Newswires Live
·
Jun 17

Rigel Pharmaceuticals publishes corporate presentation outlining commercial growth strategy and pipeline priorities

Reuters
·
Jun 17

Rigel closes license agreement for Veppanu

TIPRANKS
·
Jun 17

BRIEF-Rigel Announces Closing Of Licensing Agreement For Veppanu (Vepdegestrant)

Reuters
·
Jun 17

Rigel closes VEPPANU license deal, makes USD 70 million upfront payment

Reuters
·
Jun 17

Rigel Announces Closing of Licensing Agreement for Veppanu™ (Vepdegestrant)

THOMSON REUTERS
·
Jun 17

Rigel Pharmaceuticals Price Target Maintained With a $57.00/Share by HC Wainwright & Co.

Dow Jones
·
Jun 02

Rigel Pharma director Kamil Ali-Jackson disposes of 2,500 common shares worth $72,925

Reuters
·
May 29

Knight Therapeutics launches Tavalisse in Mexico for chronic immune thrombocytopenia

Reuters
·
May 28

Rigel Pharmaceuticals Price Target Maintained With a $57.00/Share by HC Wainwright & Co.

Dow Jones
·
May 27

Rigel CEO to Present Company Overview at Jefferies Global Healthcare Conference

Reuters
·
May 27

Rigel Pharmaceuticals Price Target Maintained With a $57.00/Share by HC Wainwright & Co.

Dow Jones
·
May 22

Rigel says Phase 3 AcceleRET-Lung trial meets primary endpoint for GAVRETO in NSCLC

Reuters
·
May 22

Rigel Announces Oral and Poster Presentations at the 2026 Asco Annual Meeting and Eha2026 Congress

THOMSON REUTERS
·
May 22

Rigel Pharmaceuticals shareholders approve amended 2018 equity incentive plan

Reuters
·
May 21